Celebrating a Team Effort to Create New Standards of Cancer Care

As we close the books on 2022, I have been reflecting on the evolution of Cullinan Oncology over the course of the year, and all that our team accomplished to further our mission to create new standards of care for patients with cancer. Every aspiration is achieved one step at a time, and for the team at Cullinan Oncology, together we have taken many steps to advance our robust and diverse portfolio of oncology assets, to foster connections within the scientific community, and to build upon our entrepreneurial and collaborative culture.

The Promise of Science at Cullinan

Cullinan’s defining characteristic is our ability to pursue modality-agnostic oncology research with a focus on identifying high-impact targets. In 2022, this strategy came to life. For our lead asset, zipalertinib, our small molecule EGFR inhibitor for non-small cell lung cancer, Cullinan entered into a strategic collaboration with Taiho Pharmaceutical and shortly after moved the asset into its pivotal study. In other pipeline advancements, CLN-049, a bispecific antibody targeting acute myeloid leukemia and myelodysplastic syndrome, and CLN-619, a pan-cancer, anti-MICA/B immunoglobulin, both entered phase 1 studies. Next year, we look forward to CLN-617, a potentially pan-cancer IL12/IL2 fusion protein and CLN-978, a tri-specific antibody targeting B-cell acute lymphoid leukemia and non-Hodgkin lymphoma, both entering clinical trials, for a total of five clinical-stage assets for Cullinan Oncology.

As we move more potentially first-in-class and best-in-class assets further into development, we do so with a sense of urgency and a relentless commitment to patients who are waiting for new therapeutic options.

Fostering Connections in the Scientific Community

Progress is best achieved together, and our diverse pipeline and science-first approach also helped deepen our relationships with the oncology and academic communities. In 2022, we presented our scientific findings through 14 posters and oral presentations across 6 programs at U.S. and global medical conferences and congresses. We also contributed our expertise and learned from our peers during symposia and panel discussions such as the BIDMC Cancer Center Symposium and the Cell Engager Summit. ?With three programs active in the clinic across the globe, we broadened our connections with key investigators and sites. ?By forging connections with industry leaders, we bring diverse perspectives and expertise to the table and support common scientific goals.

A Culture Built to Serve?

In 2022, we welcomed new talent to our exceptional team, nearly doubling the size of our workforce over the course of the year. We knew we had to be intentional about protecting our unique entrepreneurial culture as we grew. Defining and embedding our company values helped us ensure we preserved our agility while undergoing a period of rapid growth. I am really proud of our core value, namely, to impact the lives of patients and their families, which reflects the tremendous impact that cancer has not only on the patient, but on everyone who loves and cares for them.

Diverse points of view challenge our assumptions and help us identify innovative solutions, and in 2022, I signed on to the MassBio CEO pledge for a more equitable and inclusive life sciences industry. Within our company, we also committed to expanding DE&I in areas such as recruiting, onboarding and development of our workforce and the clinical trials we conduct. ?

Looking ahead to 2023, we will continue to make bold and informed decisions to both expand and accelerate our pipeline. We make those decisions because patients are waiting, and everything we strive for – past, present, and future – circles back to patients with cancer in need of effective new treatment options.